Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 1. Overview of Psoriasis and Guidelines of Care for the Treatment of Psoriasis With Biologics

J Am Acad Dermatol. 2008 May;58(5):826-50. doi: 10.1016/j.jaad.2008.02.039.

Abstract

Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this first of 5 sections of the guidelines of care for psoriasis, we discuss the classification of psoriasis; associated comorbidities including autoimmune diseases, cardiovascular risk, psychiatric/psychologic issues, and cancer risk; along with assessment tools for skin disease and quality-of-life issues. Finally, we will discuss the safety and efficacy of the biologic treatments used to treat patients with psoriasis.

Publication types

  • Consensus Development Conference
  • Practice Guideline

MeSH terms

  • Acitretin / adverse effects
  • Alefacept
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Arthritis, Psoriatic / drug therapy*
  • Biological Products / therapeutic use*
  • Cardiovascular Diseases / etiology
  • Cyclosporine / therapeutic use
  • Depression / etiology
  • Etanercept
  • Humans
  • Immunoglobulin G / adverse effects
  • Interleukin-12 / antagonists & inhibitors
  • Interleukin-23 / antagonists & inhibitors
  • Lymphoma / etiology
  • Metabolic Syndrome / complications
  • Methotrexate / adverse effects
  • Obesity / complications
  • PUVA Therapy
  • Psoriasis / complications
  • Psoriasis / drug therapy*
  • Receptors, Tumor Necrosis Factor
  • Recombinant Fusion Proteins / therapeutic use
  • Smoking / adverse effects
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Biological Products
  • Immunoglobulin G
  • Interleukin-23
  • Receptors, Tumor Necrosis Factor
  • Recombinant Fusion Proteins
  • Tumor Necrosis Factor-alpha
  • Interleukin-12
  • Cyclosporine
  • Alefacept
  • Acitretin
  • Etanercept
  • efalizumab
  • Methotrexate